These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 10510160

  • 1. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM, Nicholl DJ.
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
    Jorga K, Fotteler B, Banken L, Snell P, Steimer JL.
    Br J Clin Pharmacol; 2000 Jan; 49(1):39-48. PubMed ID: 10606836
    [Abstract] [Full Text] [Related]

  • 3. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T, Aitken JW.
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [Abstract] [Full Text] [Related]

  • 4. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M, Yokochi M, Kuno S, Hattori Y, Tsukamoto Y, Narabayashi H, Tohgi H, Mizuno Y, Kowa H, Yanagisawa N, Kanazawa I.
    J Neural Transm (Vienna); 1997 May; 104(2-3):229-36. PubMed ID: 9203084
    [Abstract] [Full Text] [Related]

  • 7. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 10. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
    Adler CH, Singer C, O'Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K.
    Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
    [Abstract] [Full Text] [Related]

  • 11. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
    Jorga K, Fotteler B, Schmitt M, Nielsen T, Zürcher G, Aitken J.
    Eur Neurol; 1997 Aug; 38(1):59-67. PubMed ID: 9252801
    [Abstract] [Full Text] [Related]

  • 12. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
    Davis TL, Roznoski M, Burns RS.
    Clin Neuropharmacol; 1995 Aug; 18(4):333-7. PubMed ID: 8665546
    [Abstract] [Full Text] [Related]

  • 13. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE.
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
    Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M.
    Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
    [Abstract] [Full Text] [Related]

  • 15. Influence of COMT inhibition on levodopa pharmacology and therapy.
    Goetz CG.
    Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
    [Abstract] [Full Text] [Related]

  • 16. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
    Muhlack S, Herrmann L, Salmen S, Müller T.
    J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
    [Abstract] [Full Text] [Related]

  • 17. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN.
    Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
    [Abstract] [Full Text] [Related]

  • 18. Tolcapone increases maximum concentration of levodopa.
    Müller T, Woitalla D, Schulz D, Peters S, Kuhn W, Przuntek H.
    J Neural Transm (Vienna); 2000 Dec; 107(1):113-9. PubMed ID: 10809409
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
    Jorga KM.
    Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
    [Abstract] [Full Text] [Related]

  • 20. Tolcapone: a novel approach to Parkinson's disease.
    Micek ST, Ernst ME.
    Am J Health Syst Pharm; 1999 Nov 01; 56(21):2195-205. PubMed ID: 10565698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.